SAN

73.045

-1.43%↓

SRT3

215.05

-3.76%↓

ORNBV.FI

68.55

+0.07%↑

PHMA

95.6

-1.49%↓

DRW3

89.85

-0.88%↓

SAN

73.045

-1.43%↓

SRT3

215.05

-3.76%↓

ORNBV.FI

68.55

+0.07%↑

PHMA

95.6

-1.49%↓

DRW3

89.85

-0.88%↓

SAN

73.045

-1.43%↓

SRT3

215.05

-3.76%↓

ORNBV.FI

68.55

+0.07%↑

PHMA

95.6

-1.49%↓

DRW3

89.85

-0.88%↓

SAN

73.045

-1.43%↓

SRT3

215.05

-3.76%↓

ORNBV.FI

68.55

+0.07%↑

PHMA

95.6

-1.49%↓

DRW3

89.85

-0.88%↓

SAN

73.045

-1.43%↓

SRT3

215.05

-3.76%↓

ORNBV.FI

68.55

+0.07%↑

PHMA

95.6

-1.49%↓

DRW3

89.85

-0.88%↓

Home・Aktien・Fagron

Fagron

Geschlossen

BrancheGesundheitswesen

24.4 1.67

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

24.4

Max

24.4

Schlüsselkennzahlen
By Trading Economics
Einkommen	-99K 45M
Verkäufe	-98K 476M
KGV Branchendurchschnitt	19.436 49.8
Dividendenrendite	1.67
Gewinnspanne	9.55
Angestellte	4,193
EBITDA	11M 98M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+20.59% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	1.67% 2.25%
Nächstes Ergebnis	30. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	138M 1.8B
Vorheriger Eröffnungskurs	22.73
Vorheriger Schlusskurs	24.4

Nachrichtenstimmung

By Acuity

50%

153 / 347 Ranking in Healthcare

Fagron Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Fagron Prognose

Kursziel

By TipRanks

20.59% Vorteil

12-Monats-Prognose

Durchschnitt 19.5 EUR 20.59%

Hoch 19.5 EUR

Tief 19.5 EUR

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Fagron – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Fagron – Dist abgegeben haben.

Stimmung

By Acuity

153 / 347 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.